secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059532
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna
--------------------------------------------------------------------------------

- Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.
- Cash, equivalents and marketable securities $327.4M including $80.7M net IPO proceeds; runway into 2027.
- Regained full global rights to wholly-owned base editors and RIGS; terminated PH1 collaboration with Moderna.
- Hemophilia A program: development candidate nomination expected mid-2024; 12-month NHP durability data in 2H 2024.
- R&D expenses $31.4M (+56% YoY); base editors expanded genome targetability 5-fold vs SpCas9.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/0000950170-24-059532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/mgx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer